Eperezolid

Eperezolid

SCHEMBL29421647

CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MAOB P27338 7/20 0.76
MAOA P21397 5/20 0.76
PTGS1 P23219 2/20 0.76
SDHA P31040 2/20 0.76
LMNA P02545 1/20 0.76
CALML3 P27482 1/20 0.76
F10 P00742 6/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Eperezolid SCHEMBL1176950 1.00 MAOB (0.76) MAOBMAOAPTGS1SDHALMNA
Eperezolid SCHEMBL186562 1.00 MAOB (0.76) MAOBMAOAPTGS1SDHALMNA
Eperezolid SCHEMBL5325217 0.99 MAOB (0.75) MAOBMAOAPTGS1SDHALMNA
Eperezolid SCHEMBL5328753 0.96 F10 (0.71) MAOBMAOAPTGS1SDHALMNA
Eperezolid SCHEMBL7497950 0.96 MAOB (0.85) MAOBMAOAPTGS1SDHALMNA
SCHEMBL6160239 0.94 F10 (0.72) MAOBMAOAPTGS1SDHALMNA
SCHEMBL6160243 0.94 F10 (0.72) MAOBMAOAPTGS1SDHALMNA
SCHEMBL4163039 0.93 MAOA (0.67) MAOBMAOAPTGS1SDHALMNA
SCHEMBL10151505 0.93 MAOB (0.76) MAOBMAOAPTGS1SDHALMNA
SCHEMBL12674054 0.92 MAOB (0.73) MAOBMAOAPTGS1SDHALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250191691-A1 METHODS FOR THE TRANSLATED ALIGNMENT OF TRANSCRIPTOMIC DATA AT SINGLE-CELL RESOLUTION CALIFORNIA INSTITUTE OF TECHNOLOGY 2025-06-12 US disclosed
US-11858946-B2 Small molecules active against gram-negative bacteria THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2024-01-02 US disclosed
CN-117222433-A Medicaments conjugated to hexose phosphate and methods of making and using the same 密西西比州立大学 2023-12-12 CN disclosed
US-20230372492-A1 DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME MISSISSIPPI STATE UNIVERSITY (US) 2023-11-23 US disclosed
EP-4221755-A1 DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME Mississippi State University (US) 2023-08-09 EP disclosed
CN-116568336-A Drug conjugates and uses thereof 休伯特兰斯医疗有限公司 2023-08-08 CN disclosed
US-20220112203-A1 SMALL MOLECULES ACTIVE AGAINST GRAM-NEGATIVE BACTERIA THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2022-04-14 US disclosed
WO-2022072425-A1 DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME PARK JOO YOUN (US) 2022-04-07 WO disclosed
CN-114206362-A Methods of treating inflammatory conditions and related infections 赛瓦图斯有限公司 2022-03-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230372492-A1 DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME GFPT1, PHPT1, SLC2A1 MAOB 3136/4885MAOA 2364/4885PTGS1 3999/4885
US-20220112203-A1 SMALL MOLECULES ACTIVE AGAINST GRAM-NEGATIVE BACTERIA PGLS, MRPL21, CLPP MAOB 503/4885MAOA 701/4885PTGS1 2694/4885
US-11858946-B2 Small molecules active against gram-negative bacteria PGLS, MRPL21, CLPP MAOB 503/4885MAOA 701/4885PTGS1 2694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.